Table 1 Demographics and key information for the study cohort.
From: Robust and durable serological response following pediatric SARS-CoV-2 infection
Time point T1 | Time point T1 | Time point T2 | Time point T2 | |
|---|---|---|---|---|
Number of participants by age group (n) | Adult (717) | Children (548) | Adult (569) | Children (402) |
Median Age – years (IQR) | 44 (37–49) | 10 (6–13) | 45 (38–50) | 10 (6–14) |
Number of females (%) | 362 (50.5) | 277 (50.6) | 297 (52.2) | 202 (50.3) |
BMI (IQR) | 25.4 (22.2–27.7) | 17.4 (14.9–19.5) | 24.7 (22.3–28.1) | 17.0 (15.0–19.7) |
Number of seropositive participants | 414 (57.7) | 181 (33.0) | 281 (49.4) | 150 (37.3) |
• Asymptomatic (%) | 36 (8.7) | 81 (44.8) | 31 (11.0) | 69 (46.0) |
• Symptomatic (%) | 378 (91.3) | 100 (55.2) | 250 (89.0) | 81 (54.0) |
Seroreverted at T2 (%) | NA | NA | 71 (17.1) | 7 (3.8) |
Symptoms at disease onset (of seropositive) | ·· | ·· | ·· | ·· |
• Fever (%) | 217 (52.4) | 66 (36.5) | 151 (53.7) | 49 (32.7) |
• Cough (%) | 221 (53.4) | 37 (20.4) | 154 (54.8) | 33 (22.0) |
• Dysgeusia (%) | 266 (64.3) | 28 (15.5) | 176 (62.6) | 24 (16.0) |
• Diarrhea (%) | 75 (18.1) | 18 (9.9) | 55 (19.6) | 16 (10.7) |
Median (IQR) days from positive PCR test result to timepoint | 96 (63–120) | 96 (63–120) | 333 (319–353) | 333 (319–353) |
Median (IQR) days from symptoms onset to timepoint (of seropositive) | 109 (67–122) | 109 (67–122) | 340 (322–356) | 340 (322–356) |
Hospitalized (of seropositive) (%) | 15 (3.6) | 0 (0.0) | NA | NA |
Vaccinated (%) | NA | NA | 24 (4.2) | 1 (0.3) |
Number of households | 328 | 328 | 279 | 279 |
Median (IQR) number of household members | 4 (3–4) | 4 (3–4) | 4 (3–4) | 4 (3–4) |
